Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.46 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15685232 | 0.84 | MAPT (0.75) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL2952066 | 0.83 | MAPT (0.65) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL1957440 | 0.83 | MAPT (0.77) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL6220192 | 0.81 | KAT2B (0.68) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL7740648 | 0.81 | KAT2B (0.64) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL6896294 | 0.81 | PRSS1 (0.53) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL26324521 | 0.80 | HCAR3 (0.63) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL17678256 | 0.80 | SMN1; SMN2 (0.67) | MAPTPOLBPKMSMN1; SMN2KAT2B | |
| SCHEMBL9979899 | 0.79 | PRSS1 (0.41) | MAPTGAAPRSS1 | |
| SCHEMBL12491626 | 0.79 | CYP19A1 (0.51) | MAPTPOLBPKMSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023692-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-01-24 | — | — | US | disclosed |
| US-20190023692-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-01-24 | — | — | US | disclosed |
| US-10081618-B2 | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus ativiral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-25 | — | — | US | disclosed |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-14 | — | — | US | disclosed |
| EP-2948444-B1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2948444-B1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2948444-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Janssen Sciences Ireland UC (IE) | 2015-12-02 | — | — | EP | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014114776-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114776-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2014-07-31 | — | — | WO | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080446-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023692-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | SQOR, SDHA, DHX15 | MAPT 4672/4885POLB 202/4885PKM 1496/4885 |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | SBDS, CHUK, HAT1 | MAPT 3472/4885POLB 160/4885PKM 942/4885 |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | ATIC, DHX15, SQOR | MAPT 4480/4885POLB 215/4885PKM 1930/4885 |
| US-10081618-B2 | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus ativiral agents | ATIC, DHX15, SQOR | MAPT 4480/4885POLB 215/4885PKM 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.